The global market for monoclonal antibody therapy was valued at USD 165.76 billion in 2021. The market is further estimated to be growing at a CAGR of 16.24% from 2021 to 2026 and worth USD 351.77 billion by 2026.
Monoclonal antibodies (mAbs), a type of monospecific antibody (protective body inflammatory response), are made up of identical antibody molecules and are produced by a single cell clone or cell line. The mAbs have brought about a fundamental change in the pharmaceutical and biotechnology industries, and in the future, they are also expected to play a crucial role in clinical protocol with the further development of these molecular agents. Monoclonal antibodies are used to fight against a variety of diseases such as autoimmune disorders, cancers, and inflammatory diseases.
Y-O-Y growth in the prevalence of cancer and chronic diseases is one of the significant factors driving the global monoclonal antibody therapy market growth.
These diseases have led to increasing demand for biologics, which in turn generates a demand for monoclonal antibodies. The growing dynamics of genetic research and development coupled with the emergence of technologically advanced genetic platforms, such as next-generation sequencing/ stem cell technology, have also contributed significantly to the market. In addition, the affordability of the research technology required to develop mAbs has also contributed to the growth of the global monoclonal antibody therapy market.
According to Cancer Research UK, in 2019 there were around 18.6 million new cancer cases and 10 million deaths worldwide. The increasing incidence of autoimmune diseases, infectious diseases, inflammatory diseases, and microbial diseases is contributing to a huge demand for mAb therapy. The production of mAbs on a large scale further encourages pharmaceutical companies to create their own product line for customized drug products. According to a study published by the NCBI, around 850 companies participated in therapeutic protein research.
The homogeneity of the mAbs also makes them suitable for experimental procedures, as they can facilitate the production of identical antibodies. Thus increasing their demand in the healthcare sector. Other factors that are positively impacting the market are increased patient and clinician awareness of mAb therapy, the introduction of better products, increasing adoption of antibodies in sensitive markets, and rapid approval by regulatory authorities for innovative monoclonal antibodies therapies. The increase in the production and identification of specific antibodies against particular antigens results in unique products in laboratories and the growing prevalence of cost-effective mAbs are driving the growth of the global monoclonal antibody therapy market.
Some problems that arise in the manufacture of mAbs include a cost-effective procedure and susceptibility to contamination. In addition, production requires additional cell culture and purification procedures to produce mAbs successfully. Other factors such as the availability of alternative treatment methods and natural remedies are gaining popularity in the world and it is expected to negatively impact the monoclonal antibody drugs market growth during the forecast period.
The monoclonal antibody therapy market is gaining opportunities using biological therapy for the treatment of different types of chronic diseases such as rheumatoid arthritis, cancer, Crohn's disease, osteoporosis, systemic lupus erythematosus, and psoriasis, etc. This disease often needs customized treatment modalities. The affirmative indication of the controlling establishments for the entry of biosimilars of the predominant mAb therapies further promotes the growth of the market, the increase of autoimmune disease cases which are expected to generate the maximum opportunity on the market growth of monoclonal antibody therapy market over the forecast period.
A disadvantage of drugs formulated from mAb is that they are very specific in nature and have limited purposes. This is because they simply interact with cells and do not penetrate them. To some extent, this has hampered the monoclonal antibody market. Another difficulty in using mAbs is that they must be injected into the body and hence are disliked by patients.
COVID-19 Impact on the global monoclonal antibody therapy market:
The monoclonal antibody therapy market growth is significantly impacted by the COVID-19 pandemic. Although, the restrictive containment measures involving social distancing, remote working, and business closures have resulted in decreasing the market revenues. A growing number of government initiatives and funding for clinical trials of drugs, which can be used in the treatment of Covid-19, are expected to support market growth, which is expected to reach between USD 80- 100 billion in 2020 &2021, growing at a CAGR by 12%. This is mainly due to the increase in R&D associated with COVID-19 vaccination.
Market Size Available
2020 to 2026
2021 to 2026
By Type, Application, Distribution channel, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global monoclonal antibody therapy market has been segmented and sub-segmented based on Type, Application, Distribution channel, and Region.
Global Monoclonal Antibody Therapy Market - By Type:
The human mAb segment held the majority share of the monoclonal antibody therapy market. The segment growth is driven by growing demand and higher sales for Humira. Furthermore, the introduction of Adalimumab biosimilars is projected to boost sector growth from 2020 to 2027. Amgen, for example, announced the introduction of Amgevita, a biosimilar of adalimumab, in Europe in October 2018.
Global Monoclonal Antibody Therapy Market -By Application:
The cancer segment augmented the largest share of the market and is expected to continue its growth during the forecast period. The segment growth is fuelled by the increased incidence of rheumatoid arthritis, the quick adoption of biological therapies, and new autoimmune illness. In addition, other factors such as favorable reimbursement policies, the proliferation of chronic diseases, and the adoption of advanced technology are driving the market growth.
Global Monoclonal Antibody Therapy Market -By Distribution Channel:
The hospital pharmacy generates significant revenue. The factors such as active government interventions for chronic diseases, improving healthcare expenditure, and favorable reimbursement policies across the countries fuel the market growth. On the other hand, the availability of advanced infrastructure, increasing prevalence of cancer cases, and improving focus by the manufacturers across the regions are expanding the hospital pharmacy segment growth.
Global Monoclonal Antibody Therapy Market – By Region:
Based on region, North America occupies a dominant position in the market due to the presence of well-established healthcare infrastructure, the government's emphasis on infection control and management, and a higher prevalence of lifestyle-related diseases. The United States is expected to control the North American market. The U.S market will continue on its upward trajectory due to increased government funding for cancer research and technology development.
According to American Cancer Society estimates for the year 2020 in the United States, approximately 1,855,950 new cancer cases and 606,550 cancer deaths have been estimated, which are expected to continue in the future by fueling the market demand. For example, the National Institute of Standards and Technology bio-fabrication initiative in the United States provides scientifically sound regulatory guidance to ensure the efficient and safe manufacture of protein therapies and to help biopharmaceutical manufacturers deliver high-quality protein drugs and low cost all over the world.
The European market will gain market revenues owing to government initiatives aimed at enabling profitable mAb production are expected to foster the emergence of this sector during the forecast period.
In the future, Asia-Pacific is also expected to show tremendous growth due to the increased spending on research and development, high purchase rate, and growing patient awareness for the therapeutic use of mAbs. China has significant growth potential in the APAC region due to the favorable government initiatives supporting the research and treatment for mAbs applications, the increase in funded R&D projects for the development of cheaper mAbs. For example, government donors such as the National Foundation of Natural Sciences and the National Basic Research Program of China provide financial support to companies and universities to conduct research and development on mAbs.
The LATAM market will also offer solid growth promises for the future.
KEY MARKET PLAYERS:
Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd are some of the dominating companies in the global monoclonal antibody therapy market.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Scope of the report
1.3 Study Assumptions
1.4 Base Currency, Base Year and Forecast Periods
2. Research Methodology
2.1 Analysis Design
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Data Modelling
2.2.4 Expert Validation
2.3 Study Timeline
3. Report Overview
3.1 Executive Summary
3.2 Key Inferencees
4. Market Dynamics
4.1 Impact Analysis
4.2 Regulatory Environment
4.3 Technology Timeline & Recent Trends
5. Competitor Benchmarking Analysis
5.1 Key Player Benchmarking
5.1.1 Market share analysis
5.1.3 Regional Presence
5.2 Mergers & Acquistion Landscape
5.3 Joint Ventures & Collaborations
6. Market Segmentation
6.1 Global Monoclonal Antibody Therapy Market - By Type:
6.1.1 Human mAb
6.1.2 Humanized mAb
6.1.3 Chimeric mAb
6.1.4 Murine mAb
6.1.5 Market Size Estimations & Forecasts (2021-2026)
6.1.6 Y-o-Y Growth Rate Analysis
6.1.7 Market Attractiveness Index
6.2 Global Monoclonal Antibody Therapy Market -By Application:
6.2.2 Autoimmune Diseases
6.2.3 Market Size Estimations & Forecasts (2021-2026)
6.2.4 Y-o-Y Growth Rate Analysis
6.2.5 Market Attractiveness Index
6.3 Global Monoclonal Antibody Therapy Market -By Distribution Channel:
6.3.1 Hospital Pharmacy Retail Pharmacy
6.3.2 Online Pharmacy
6.3.3 Market Size Estimations & Forecasts (2021-2026)
6.3.4 Y-o-Y Growth Rate Analysis
6.3.5 Market Attractiveness Index
7. Geographical Landscape
7.1 Global Identity Governance and Administration Market, by Region
7.2 North America - Market Analysis (2021 - 2026)
7.2.1 By Country
7.2.2 By Type
7.2.3 By Application
7.2.4 By Distribution Channel:
7.3.1 By Country
184.108.40.206 Rest of Europe
7.3.2 By Type
7.3.3 By Application
7.3.4 By Distribution Channel:
7.4 Asia Pacific
7.4.1 By Country
220.127.116.11 South Korea
18.104.22.168 South East Asia
22.214.171.124 Australia & NZ
126.96.36.199 Rest of Asia-Pacific
7.4.2 By Type
7.4.3 By Application
7.4.4 By Distribution Channel:
7.5 Latin America
7.5.1 By Country
188.8.131.52 Rest of Latin America
7.5.2 By Type
7.5.3 By Application
7.5.4 By Distribution Channel:
7.6 Middle East and Africa
7.6.1 By Country
184.108.40.206 Middle East
7.6.2 By Type
7.6.3 By Application
7.6.4 By Distribution Channel:
8. Key Player Analysis
8.1 Pfizer Inc.
8.1.1 Business Description
8.1.4 SWOT Analysis
8.1.5 Recent Developments
8.1.6 Analyst Overview
8.2 Novartis AG
8.3 Bayer AG
8.4 Sanofi S.A.
8.5 CASI Pharmaceuticals
8.6 Eli Lilly and Co.
8.7 Merck & Co., Inc.
8.8 Changchun Zhongyingfeng Science And Technology Co., Ltd
8.9 Hangzhou Immuno Biotech Co. Ltd
8.10 Nantong Egens Biotechnology Co. Ltd
9. Market Outlook & Investment Opportunities
List of Tables
List of Figures
Global, regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped.
The segment-level analysis in terms of type, application, distribution channel, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.
A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies
An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.